Systemic inflammation is associated with chronic obstructive pulmonary disease (COPD) and many other chronic diseases. It is increasingly recognized that individuals with COPD frequently have underlying comorbidities including cardiovascular disease, skeletal muscle dysfunction, depression and anxiety, obstructive sleep apnea, osteoporosis, gastroesophageal reflux disease, anemia, lung cancer, cognitive impairment, diabetes, renal insufficiency, and chronic infections. The link between systemic inflammation, COPD, and its common comorbidities is incompletely understood. However, persons with COPD and comorbidities have a reduced quality of life and functional status, utilize more health care resources, and are at higher risk of hospitalization and death. Screening for and treating comorbidities are important in the integrated care of the COPD patient and may have a substantial impact on morbidity and mortality.
*Division of Pulmonary, Critical Care, and Sleep Medicine, Drexel University College of Medicine, Philadelphia, PA
†Section of Pulmonary, Critical Care, and Sleep Medicine, Yale University School of Medicine, New Haven
‡VA Connecticut Healthcare System, West Haven, CT
Disclosure: C.L.R. serves on the COPD advisory board for and receives research funding from Glaxo Smith Kline (GSK) pharmaceuticals Inc., and has received research funding from Boehringer Ingelheim to participate in multicenter clinical trials in the past. The remaining authors declare that they have no conflicts of interest.
Address correspondence to: Jessica F. Most, MD, Division of Pulmonary, Critical Care, and Sleep Medicine, Drexel University College of Medicine, 245 North 15th Street, Mailstop 107, Philadelphia, PA 19102. E-mail: firstname.lastname@example.org.